1	Incidence of chikungunya virus infections among Kenyan children with
2	neurological disease: a prospective cohort study
3	Doris K. Nyamwaya ¹ , Mark Otiende ¹ , Lilian Mwango ¹ , Symon M. Kariuki ¹ , Berrick Otieno ¹ , Donwilliams
4	O. Omuoyo ¹ , George Githinji ¹ , Barnes S. Kitsao ¹ , Henry K. Karanja ¹ , John N. Gitonga ¹ , Zaydah R. de
5	Laurent ¹ , Alun Davies ¹ , Salim Mwarumba ¹ , Charles N. Agoti ¹ , Samuel M. Thumbi ^{2,3,4} , Mainga M.
6	Hamaluba ¹ , Charles R. Newton ¹ , Philip Bejon ^{1,5} , George M. Warimwe ^{1,5}
7	¹ KEMRI-Wellcome Trust Research Programme, Kenya; ² Paul G Allen School for Global Animal Health,
8	Washington State University, USA; ³ Institute of Immunology and Infection Research, University of
9	Edinburgh, UK; ⁴ Center for Epidemiological Modelling and Analysis, Institute of Tropical and Infectious
10	Diseases, University of Nairobi, Kenya; ⁵ Centre for Tropical Medicine and Global Health, University of
11	Oxford, UK
12	
13	Correspondence:
14	George Warimwe, KEMRI-Wellcome Trust Research Programme, P.O. Box 230-80108, Kilifi, Kenya
15	Email: george.warimwe@ndm.ox.ac.uk; Phone: +254(0)709 983 000
16	
17	ABSTRACT
18	Background. Neurological complications due to chikungunya virus (CHIKV) infection have been described
19	in different parts of the world, with children being disproportionately affected. However, the burden of
20	CHIKV-associated neurological disease in Africa is currently unknown.
21	Methods. We estimated the incidence of CHIKV infection among children hospitalised with neurological
22	disease in coastal Kenya. We used reverse-transcriptase polymerase chain reaction (RT-PCR) to
23	systematically test for CHIKV in cerebrospinal fluid (CSF) samples from children aged <16 years
24	hospitalised with symptoms of neurological disease at Kilifi County Hospital between January 2014 and

- 25 December 2018. Clinical records were linked to the Kilifi Health and Demographic Surveillance System and
- 26 population incidence rates of CHIKV infection estimated.
- 27 *Findings*. There were 18,341 paediatric admissions during the 5-year study period, of which 4,332 (24%)
- 28 had CSF collected. The most common clinical reasons for CSF collection were impaired consciousness,
- seizures and coma (47%, 22% and 21% of all collections, respectively). After acute investigations done for
- 30 immediate clinical care, CSF samples were available for 3,980 admissions, of which 367 (9.2%) were
- 31 CHIKV RT-PCR positive. The annual incidence of CHIKV-associated neurological disease varied between
- 32 13 to 58 episodes per 100,000 person-years among all children <16 years old. Among children aged <5
- 33 years, the incidence of CHIKV-associated neurological disease was 77 per 100,000 person-years, compared
- 34 with 20 per 100,000 for cerebral malaria and 7 per 100,000 for bacterial meningitis during the study period.
- 35 *Interpretation*. Although not previously recognized, CHIKV-associated neurological disease is common in
- 36 coastal Kenya and a significant public health burden.
- 37

38 INTRODUCTION

39 Chikungunya virus (CHIKV) is a positive sense RNA virus of the Alphavirus genus that was first discovered

40 in Tanzania in 1953 [1]. CHIKV is transmitted between humans by *Aedes aegypti* and *Ae. albopictus*

41 mosquitoes [2] which have facilitated its rapid global spread and the numerous chikungunya fever (CHIKF)

42 epidemics reported to date [3]. In adults, CHIKF is characterized by abrupt onset of fever and debilitating

43 muscle and joint pain, following an incubation period of about 2 to 10 days [4]. Most infections are self-

44 limiting, but joint and musculoskeletal pain may persist for months to years in some individuals [4].

45 However, unlike adults, young children rarely present with musculoskeletal symptoms but are more likely to

46 be hospitalised with CHIKV-associated neurological disease [5-10]. No specific therapeutics or licensed

47 vaccines are available for CHIKF and, in the absence of pathognomonic clinical features, confirmatory

- 48 diagnosis relies on laboratory detection of CHIKV in clinical samples [4].
- 49 CHIKV transmission is widely reported in Africa [3], with endemic febrile disease being particularly
- 50 common in children [11-14]. In 2004, one of the largest CHIKF epidemics on record began in coastal Kenya
- and spread rapidly along the East African coast and to islands in the Indian Ocean [15-17]. During that

- 52 epidemic, severe neurological manifestations of CHIKF were described in children in La Reunion [6, 18],
- 53 including disease in neonates suggesting mother-to-child virus transmission [19, 20]. CHIKV-associated
- neurological disease has since been reported in other geographical settings [5, 8], except Africa.
- 55 Recent analysis identified a high, previously unrecognized, burden of endemic CHIKF in children presenting
- at outpatient primary care facilities in coastal Kenya [14]. Here, we used an established ward surveillance at
- 57 Kilifi County Hospital on the north coast of Kenya, to estimate the incidence of CHIKV-associated
- 58 neurological disease among children in this setting. Cerebrospinal fluid (CSF) samples taken for clinical
- reasons at the hospital are routinely stored and clinical records linked to the Kilifi Health and Demographic
- 60 Surveillance System (KHDSS), allowing estimation of population incidence rates [21]. We therefore
- 61 systematically tested these stored CSF samples to establish whether evidence of infection by CHIKV is
- 62 common among children admitted to hospital with neurological illness in coastal Kenya.
- 63

64 METHODS

65 Clinical surveillance

66 Kilifi County Hospital is a referral public hospital in rural coastal Kenya with approximately 4,000 paediatric 67 admissions annually. The hospital's catchment area includes the approximately 290,000 KHDSS residents 68 who account for ~40-50% of all admissions and are enumerated during household census rounds conducted 69 every four months [21]. Malaria transmission is endemic in the demographic surveillance area with seasonal 70 rains occurring in April-June and October-December [22]. The paediatric service at Kilifi County Hospital 71 includes two wards; a 70-bed general ward and a 15-bed high dependency unit (HDU) staffed by research 72 clinicians and nurses. The HDU admits children with serious illness requiring more intensive monitoring and 73 management but has no ventilation facilities or renal replacement therapy. Electronic case records are kept 74 for all admissions including demographics, vital signs, clinical history and examination, as well as routine 75 laboratory investigations such as malaria blood slides, and blood and CSF culture. Each patient is assigned a 76 discharge diagnosis by the attending clinician following review of the notes and results. All data are linked to 77 the KHDSS database in real time by means of unique person identifiers.

78 For this study, all children aged <16 years whose illness required sampling and analysis of CSF were eligible 79 for inclusion. The decision to collect CSF was made by clinicians. The same senior clinicians oversaw care 80 throughout the period of surveillance. Where acute coma was present, the medical team considered the risks 81 of lumbar puncture versus clinical benefits of diagnostic information from a clinical management perspective 82 without reference to research considerations. Where clinically appropriate, delayed lumbar punctures were 83 conducted after a period of treatment. Neuroimaging was not available on site during the period of 84 surveillance. After investigations done for immediate clinical care, an aliquot of CSF was stored at -80°C and 85 used for CHIKV testing by RT-PCR as described below. Ethical approval was provided by the Kenya 86 Medical Research Institute Scientific and Ethics Review Unit (SSC No. 3296) and written informed consent 87 provided by parents or guardians of all study participants.

88 Detection of CHIKV infection

89 Total RNA was isolated from 100µl of each CSF sample using TRIzol[™] Reagent (ThermoFisher). A

90 published primer-probe set targeting the CHIKV non-structural protein 1 (nsP1) region [23] was then used to

91 detect CHIKV viral RNA using the Taqman® Fast Virus RT-PCR kit (ThermoFisher) on a 7500 Real-Time

92 PCR System (Applied Biosystems) in a 10µl reaction volume comprising: 3µl of 4x Taqman® Fast Virus 1-

step master mix, 5µl RNA, and primers (CHIKV 874, CHIKV 961) and probe (CHIKV 899) [23] at final

94 concentrations of 800nM and 200nM, respectively. RT-PCR conditions were; reverse-transcription at 50°C

95 for 5 min, RT inactivation/initial activation 95°C for 20 sec and 45 cycles of denaturation at 95°C for 3sec

96 and annealing/extension at 60°C for 30 sec [14]. A positive result was defined as a cycle threshold (Ct) value

97 of <40, with viral RNA from a cultured CHIKV isolate and RT-PCR mastermix without template used as

98 positive and negative controls, respectively [14].

99 Statistical analysis

All children hospitalised during the study period and whose illness required sampling and analysis of CSF were included in the analysis. Demographic and clinical features were compared between CHIKV positive and CHIKV negative admissions using Chi2 test for categorical variables and Mann-Whitney U test for continuous variables. Cerebral malaria was defined as admission with a *Plasmodium falciparum* parasite density >2,500/µl of blood and a Blantyre Coma Score (BCS) <3, while impaired consciousness was defined as BCS 3 or 4 [22, 24]. Acute bacterial meningitis was defined as either: i) a positive CSF bacterial culture or

106 latex agglutination test, or ii) bacteraemia accompanied by a CSF-to-blood glucose ratio <0.1, or iii) 107 bacteraemia accompanied by CSF white blood cell count \geq 50 $\square \times \square 10^6$ cells/L [25, 26]. We required evidence 108 of bacteria in CSF or in blood in the case definition of meningitis to maximise specificity, since there are no 109 data on glucose or CSF cell counts for CHIKV infection in our setting. Incidence of CHIKV-associated 110 neurological disease among KHDSS residents was calculated by dividing the number of CHIKV positive 111 admissions by the total person-years of observation during the 5-year study period and expressed per 112 100,000 person-years observed. For comparison, incidence estimates for cerebral malaria and acute bacterial 113 meningitis were also calculated. Incidence rate ratios were estimated using Poisson regression models and 114 compared between socio-demographic variables. All analyses were carried out in STATA/IC version 15.1 115 (StataCorp College Station, Texas, USA). We also examined the geographical distribution of cases of 116 CHIKV infection, cerebral malaria, meningitis and other admissions across the KHDSS area by mapping 117 (using QGIS version 3.10) the geolocations of homes where the children lived at the time of admission. 118 These data on residence are collected and routinely updated by the KHDSS.

119 **Role of the funding source**

120 The funders had no role in the design of the study, data collection, analysis and interpretation, or writing of 121 the report. The corresponding author had full access to all data in the study and had final responsibility for 122 the decision to submit for publication.

123

124

125 **RESULTS**

Between January 2014 and December 2018, 18341 children aged <16 years were admitted at Kilifi County Hospital, of whom 4332 (24%) had CSF collected for routine investigations (Figure 1). The most common clinical indications for CSF collection were coma, impaired consciousness and seizures which together accounted for 90% of all CSF collections (Figure S1). Similar proportions of children with these lumbar puncture indications had CSF collected across the 5-year study period, suggesting a consistent pattern of clinical practice throughout (Figure S2). After acute investigations were done for immediate clinical care,

stored CSF was available for 3980 (92%) of the 4332 admissions and these were screened for CHIKV

133 infection (Figure 1).

- 134 Of the 3980 admissions among children aged <16 years, 367 (9.2%, 95% CI 8.3, 10.2) were CHIKV RT-
- 135 PCR positive. Most of these CHIKV infections (308 of the 367; 84%) were in children aged under 5 years
- 136 (Table 1). RT-PCR assay cycle threshold values for CHIKV positive samples showed no correlation with age
- 137 (Spearman's rho=-0.09, p=0.07). CHIKV RT-PCR positivity was highest in 2016 (18%), when an epidemic
- 138 was reported in Kenya [27], and ranged between 4% to 9% in the other years (Table 1). CHIKV infection
- showed no association with HIV, bacteraemia or malaria parasitaemia at the time of admission (Table 1).
- 140 Further, the distribution of clinical history and symptoms recorded at admission and laboratory investigations
- 141 undertaken to inform clinical care was similar for CHIKV positive and CHIKV negative children (Table 1).
- Among children below 3 months of age, the majority (1352/1789; 75%) of CSF samples were taken from
- 143 newborns in the first week of life in whom we observed high CHIKV positivity rates (8.7%, 95% CI 7.3,
- 144 10.3: Table S2) suggesting mother-to-child CHIKV transmission [28].
- 145 Overall mortality among all 18341 admissions aged <16 years was 9.0% (95% CI 8.6, 9.4; 1653 deaths).
- 146 Mortality among the 4332 admissions that had CSF collected during the study period (Figure 1) was 3.2%
- 147 (95% CI 2.7, 3.8; 139 deaths), compared with 10.8% (95% CI 10.3, 11.3; 1514 deaths) in those where CSF
- 148 was not collected (Figure S3). A similar pattern was observed among newborns in the first week of life,
- 149 where overall mortality was 17.7% (95% CI 16.5, 18.8), whereas mortality in those whose CSF was
- 150 collected was 2.5% (39 deaths) compared with 25.3% (773 deaths) in those where CSF was not collected.
- 151 Overall case fatality among CHIKV positive children was 1.4% (95% CI 0.4, 3.2; 5 deaths of 367 CHIKV
- positive children) and 3.2% (95% CI 2.6, 3.8; 115 deaths) among CHIKV negative children (Table 1).
- 153 To estimate the incidence of CHIKV-associated neurological disease we took the numerator as CHIKV RT-
- 154 PCR positive admissions among KHDSS residents (i.e., 207 cases were from KHDSS residents out of the
- 155 367 cases presenting to the hospital; Figure 2) and the denominator as the total person-years observed in the
- 156 KHDSS during the 5-year study period for children aged <16 years (691,588 person-years; Table 2). The
- 157 overall incidence of CHIKV-associated neurological disease within the KHDSS was 30 per 100,000 person-
- 158 years (95% CI 26.1, 34.3) and showed no significant variation by sex or season (Table 2). Disease incidence
- 159 was highest during the 2016 epidemic but a substantial number of presentations with CHIKV infection were

160 also detected in other years (Table 2). CHIKV-associated neurological disease cases were distributed 161 throughout the KHDSS area (Figure 2). A strong inverse relationship was observed between the incidence of 162 CHIKV infection and age, estimated at 77 per 100,000 person-years in all children aged <5 years and 7 per 163 100,000 person-years among children aged \geq 5 years (Table 2). During the same period, we calculated the 164 corresponding incidences of cerebral malaria and bacterial meningitis in children aged <5 years to be 20 per 165 100,000 and 7 per 100,000 person-years, respectively (Table 2). The corresponding incidence of cerebral 166 malaria and bacterial meningitis in children aged ≥ 5 years was 5 per 100,000 and 7 per 100,000 person-167 years, respectively (Table 2).

168

169 **DISCUSSION**

170 We show that CHIKV is endemic in coastal Kenya, with viral RNA detected in approximately 9% of all CSF

samples in a county referral hospital. We also find that the risk of CHIKV infection is highest in infants with

disease being rare in older children, consistent with acquisition of immunity [14]. We show that CHIKV

173 infections are common among newborns in our setting, within the first week of life, suggesting mother-to-

174 child virus transmission as has been observed by others [19, 28]. None of the clinical or laboratory features

175 available in our dataset could reliably distinguish CHIKV-associated illness from other causes of

176 neurological disease, including meningism, seizures or coma, though fontanelle bulging was common among

177 CHIKV positive neonates. Hence in the absence of specific laboratory diagnostics the disease burden of

178 CHIKV among children with neurological illness is hidden.

179 92% of children had meningism, coma, seizures or mild reductions in Blantyre Coma Score that did not meet

the threshold for coma as the indication for CSF collection. The mortality among CHIKV positive children

181 was low, despite coma in 22% and depressed levels of consciousness in 47%. The decision to collect CSF

182 via lumbar puncture was based on clinical priorities rather than research criteria. Even in those without

183 obvious indications for CSF collection, the illness must have appeared sufficiently significant to clinicians to

184 justify hospital admission and lumbar puncture. No specific treatment is available for CHIKV infection.

185 Diagnosis would improve antibiotic stewardship and avoid treatment costs. However, the sickest patients are

186 likely to die before CSF can be collected as clinicians are less likely to collect CSF in the first 24 hours when

a patient presents in acute coma. During the 5-year period of monitoring 632 children with coma did not

188 have CSF collected, of whom 248 (i.e., 39.2%) died, compared to 530 children with coma who did have CSF

189 collected, 20 of whom died (i.e., 3.7%) (see Figure S3). Children with coma may not have CSF collected

190 acutely if clinicians are concerned about raised intracranial pressure, and on clinical recovery clinicians or

191 families may decide to forego lumbar puncture. Our data suggest that children in whom CSF is not collected

- are at high risk of death, and it is therefore possible that CHIKV is a cause of mortality among these
- 193 children. Future studies using IgM serology against CHIKV will help address this.
- 194 When comparing CHIKV-positive and CHIKV-negative children, none of the clinical symptoms or

195 laboratory tests showed differences that were substantial enough for diagnostic use in clinical practice.

196 Diagnostic uncertainty in the absence of CHIKV RT-PCR testing (or other laboratory tests such as CHIKV

197 IgM serology) may be clinically challenging. For instance, treating children for possible culture-negative

bacterial meningitis is costly and contributes to antimicrobial resistance in a hospital setting. Neuroimaging

is difficult to access in our setting and usually requires costs to be borne by parents. Capacity for definitive

200 molecular or serological testing is therefore required for confirmatory diagnosis of a disease that appears to

201 be a common cause of admission in young children in coastal Kenya.

202 We observed CHIKV infections during and outside an epidemic year suggesting endemic CHIKV

transmission in coastal Kenya. With the linkage to demographic surveillance, we estimate an incidence of 77

204 CHIKV-positive admissions per 100,000 person-years among children aged <5 years. This incidence is

higher than recent incidences for bacterial meningitis which we estimate at 7 per 100,000 person-years, or

for invasive bacterial diseases such as 37 per 100,000 for invasive salmonellosis or 3 per 100,000 for

207 invasive pneumococcal disease [25, 29], and almost four times the incidence of cerebral malaria (20 per

208 100,000) in the same age group [22]. Following the reductions in severe malaria due to falling malaria

transmission [22], and reductions in bacterial meningitis after vaccination [25], CHIKV may now be one of

210 the most common causes of hospitalization with neurological disease among children aged <5 years in

211 coastal Kenya.

212 The study has some limitations. We defined cases based on PCR detection of viral RNA which likely

213 underestimated the true burden of CHIKV due to the short duration of viral RNA detection in tissues during

214 CHIKV infections [30]. Furthermore, we are likely to have underestimated more severe CHIKV infections

since CSF is unlikely to be collected from the most severely unwell children. We did not screen for other

216 viruses that have been associated with neurological disease in Africa (e.g., adenovirus, herpesvirus and 217 others [31]), and this warrants future study. Further studies are also needed to determine the nature and 218 timing of mother-to-child CHIKV transmission, including maternal CHIKV screening as done by others 219 [20]. The study was limited to a single geographical location on the Kenyan coast and our estimate of disease 220 incidence was based on the KHDSS population as denominator, which generally accounts for 40-50% of all 221 admissions at Kilifi County Hospital. However, CHIKV infections showed little geographical heterogeneity 222 within the County, supporting generalizability of these results. 223 CHIKV mosquito vectors are widely distributed on the East African coast and reporting of cases of CHIKV 224 infections in Africa is widespread. Despite this, surveillance for CHIKV in CSF samples has not been

undertaken systematically in Africa and should now be an urgent priority to describe this previously

226 unidentified public health burden. Such work will provide the foundation for future research on preventive

and therapeutic interventions.

228

229 ACKNOWLEDGEMENTS

230 This work was commissioned by the National Institute for Health Research (NIHR) Global Health Research

programme (16/136/33) using UK aid from the UK Government. The views expressed in this publication are

those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

233 GMW is supported by an Oak foundation fellowship and a Wellcome Trust grant (grant number

234 203077_Z_16_Z). This manuscript was submitted for publication with permission from the Director of the

235 Kenya Medical Research Institute. This research was funded in part by the Wellcome Trust grant number

236 203077_Z_16_Z. For the purpose of Open Access, the author has applied a CC-BY public copyright licence

to any author accepted manuscript version arising from this submission.

238

239 AUTHORS' CONTRIBUTIONS

240 DKN: Investigation, Formal Analysis, Methodology, Writing - review & editing

241 MO: Formal Analysis, Visualisation, Methodology, Writing - review & editing

- 242 LM: Data Curation, Writing review & editing
- 243 SMK: Formal Analysis, Writing review & editing
- 244 BO: Formal Analysis, Writing review & editing
- 245 DOO: Investigation, Methodology, Writing review & editing
- 246 GG: Investigation, Validation, Writing review & editing
- 247 BK: Data Curation
- 248 HKK: Investigation, Writing review & editing
- 249 JNG: Investigation, Writing review & editing
- 250 ZRL: Investigation, Writing review & editing
- 251 AD: Visualisation, Writing review & editing
- 252 SM: Investigation, Writing review & editing
- 253 CNA: Investigation, Validation, Writing review & editing
- 254 SMT: Supervision, Writing review & editing
- 255 MMH: Project Administration, Writing review & editing
- 256 CRN: Supervision, Writing review & editing
- 257 PB: Conceptualisation, Formal Analysis, Writing review & editing
- 258 GMW: Conceptualisation, Funding acquisition, Supervision, Investigation, Project Administration, Formal
- 259 Analysis, Writing original draft, Writing review & editing
- 260

261 CONFLICT OF INTEREST

262 All authors declare no conflicts of interest.

263

264 **REFERENCES**

- 265 1. Ross RW. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to
- 266 the epidemic. J Hyg (Lond). 1956;54(2):177-91. Epub 1956/06/01. doi: 10.1017/s0022172400044442.
- 267 PubMed PMID: 13346078; PubMed Central PMCID: PMCPMC2218030.
- 268 2. Weaver SC, Chen R, Diallo M. Chikungunya Virus: Role of Vectors in Emergence from Enzootic
- 269 Cycles. Annu Rev Entomol. 2020;65:313-32. Epub 2019/10/09. doi: 10.1146/annurev-ento-011019-025207.
- 270 PubMed PMID: 31594410.

271 3. Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus: mapping the 64-year

272 history. Int J Infect Dis. 2017;58:69-76. Epub 2017/03/16. doi: 10.1016/j.ijid.2017.03.006. PubMed PMID:

- **273 28288924**.
- 4. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N
- 275 Engl J Med. 2015;372(13):1231-9. Epub 2015/03/26. doi: 10.1056/NEJMra1406035. PubMed PMID:

276 25806915.

5. Kumar S, Agrawal G, Wazir S, Kumar A, Dubey S, Balde M, et al. Experience of Perinatal and

278 Neonatal Chikungunya Virus (CHIKV) Infection in a Tertiary Care Neonatal Centre during Outbreak in

279 North India in 2016: A Case Series. J Trop Pediatr. 2019;65(2):169-75. Epub 2018/06/13. doi:

280 10.1093/tropej/fmy032. PubMed PMID: 29893939.

281 6. Gerardin P, Couderc T, Bintner M, Tournebize P, Renouil M, Lemant J, et al. Chikungunya virus-

associated encephalitis: A cohort study on La Reunion Island, 2005-2009. Neurology. 2016;86(1):94-102.

283 Epub 2015/11/27. doi: 10.1212/WNL.00000000002234. PubMed PMID: 26609145.

284 7. Cerny T, Schwarz M, Schwarz U, Lemant J, Gerardin P, Keller E. The Range of Neurological

285 Complications in Chikungunya Fever. Neurocrit Care. 2017;27(3):447-57. Epub 2017/07/26. doi:

286 10.1007/s12028-017-0413-8. PubMed PMID: 28741102.

287 8. Dorleans F, Hoen B, Najioullah F, Herrmann-Storck C, Schepers KM, Abel S, et al. Outbreak of

288 Chikungunya in the French Caribbean Islands of Martinique and Guadeloupe: Findings from a Hospital-

- 289 Based Surveillance System (2013-2015). Am J Trop Med Hyg. 2018;98(6):1819-25. Epub 2018/04/26. doi:
- 290 10.4269/ajtmh.16-0719. PubMed PMID: 29692295; PubMed Central PMCID: PMCPMC6086161.
- 9. Mehta R, Gerardin P, de Brito CAA, Soares CN, Ferreira MLB, Solomon T. The neurological
- 292 complications of chikungunya virus: A systematic review. Rev Med Virol. 2018;28(3):e1978. Epub
- 293 2018/04/20. doi: 10.1002/rmv.1978. PubMed PMID: 29671914; PubMed Central PMCID:
- 294 PMCPMC5969245.
- 295 10. Samra JA, Hagood NL, Summer A, Medina MT, Holden KR. Clinical Features and Neurologic
- 296 Complications of Children Hospitalized With Chikungunya Virus in Honduras. J Child Neurol.
- 297 2017;32(8):712-6. Epub 2017/05/02. doi: 10.1177/0883073817701879. PubMed PMID: 28459170.
- 298 11. Chipwaza B, Mugasa JP, Selemani M, Amuri M, Mosha F, Ngatunga SD, et al. Dengue and
- 299 Chikungunya fever among viral diseases in outpatient febrile children in Kilosa district hospital, Tanzania.
- 300 PLoS Negl Trop Dis. 2014;8(11):e3335. Epub 2014/11/21. doi: 10.1371/journal.pntd.0003335. PubMed
- 301 PMID: 25412076; PubMed Central PMCID: PMCPMC4239002.
- 302 12. Hertz JT, Munishi OM, Ooi EE, Howe S, Lim WY, Chow A, et al. Chikungunya and dengue fever
- among hospitalized febrile patients in northern Tanzania. Am J Trop Med Hyg. 2012;86(1):171-7. Epub
- 304 2012/01/11. doi: 10.4269/ajtmh.2012.11-0393. PubMed PMID: 22232469; PubMed Central PMCID:
- 305 PMCPMC3247127.
- 306 13. Waggoner J, Brichard J, Mutuku F, Ndenga B, Heath CJ, Mohamed-Hadley A, et al. Malaria and
- 307 Chikungunya Detected Using Molecular Diagnostics Among Febrile Kenyan Children. Open Forum Infect
- 308 Dis. 2017;4(3):ofx110. Epub 2017/07/14. doi: 10.1093/ofid/ofx110. PubMed PMID: 28702473; PubMed
- 309 Central PMCID: PMCPMC5505337.
- 14. Nyamwaya DK, Otiende M, Omuoyo DO, Githinji G, Karanja HK, Gitonga JN, et al. Endemic
 chikungunya fever in Kenyan children: a prospective cohort study. BMC Infect Dis. 2021;21(1):186. Epub
 2021/02/20. doi: 10.1186/s12879-021-05875-5. PubMed PMID: 33602147; PubMed Central PMCID:
 PMCPMC7889702.
- Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue CH, Kelly CH, et al. Tracking
 epidemic Chikungunya virus into the Indian Ocean from East Africa. J Gen Virol. 2008;89(Pt 11):2754-60.
 Epub 2008/10/22. doi: 10.1099/vir.0.2008/005413-0. PubMed PMID: 18931072; PubMed Central PMCID:
 PMCPMC3347796.

12

- 318 16. Sang RC, Ahmed O, Faye O, Kelly CL, Yahaya AA, Mmadi I, et al. Entomologic investigations of a
- 319 chikungunya virus epidemic in the Union of the Comoros, 2005. Am J Trop Med Hyg. 2008;78(1):77-82.
- 320 Epub 2008/01/12. PubMed PMID: 18187788.
- 321 17. Sergon K, Yahaya AA, Brown J, Bedja SA, Mlindasse M, Agata N, et al. Seroprevalence of
- 322 Chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg.
- 323 2007;76(6):1189-93. Epub 2007/06/09. PubMed PMID: 17556634.
- 18. Robin S, Ramful D, Le Seach F, Jaffar-Bandjee MC, Rigou G, Alessandri JL. Neurologic
- 325 manifestations of pediatric chikungunya infection. J Child Neurol. 2008;23(9):1028-35. Epub 2008/02/22.
- doi: 10.1177/0883073808314151. PubMed PMID: 18287573.
- 19. Ramful D, Carbonnier M, Pasquet M, Bouhmani B, Ghazouani J, Noormahomed T, et al. Mother-to-
- 328 child transmission of Chikungunya virus infection. Pediatr Infect Dis J. 2007;26(9):811-5. Epub 2007/08/28.
- doi: 10.1097/INF.0b013e3180616d4f. PubMed PMID: 17721376.
- 330 20. Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, et al. Multidisciplinary
- 331 prospective study of mother-to-child chikungunya virus infections on the island of La Reunion. PLoS Med.
- 332 2008;5(3):e60. Epub 2008/03/21. doi: 10.1371/journal.pmed.0050060. PubMed PMID: 18351797; PubMed
- 333 Central PMCID: PMCPMC2267812.
- 21. Scott JA, Bauni E, Moisi JC, Ojal J, Gatakaa H, Nyundo C, et al. Profile: The Kilifi Health and
- 335 Demographic Surveillance System (KHDSS). Int J Epidemiol. 2012;41(3):650-7. Epub 2012/05/01. doi:
- 336 10.1093/ije/dys062. PubMed PMID: 22544844; PubMed Central PMCID: PMCPMC3396317.
- 22. Njuguna P, Maitland K, Nyaguara A, Mwanga D, Mogeni P, Mturi N, et al. Observational study: 27
- 338 years of severe malaria surveillance in Kilifi, Kenya. BMC Med. 2019;17(1):124. Epub 2019/07/10. doi:
- 339 10.1186/s12916-019-1359-9. PubMed PMID: 31280724; PubMed Central PMCID: PMCPMC6613255.
- 23. Lanciotti RS, Kosoy OL, Laven JJ, Panella AJ, Velez JO, Lambert AJ, et al. Chikungunya virus in
- 341 US travelers returning from India, 2006. Emerg Infect Dis. 2007;13(5):764-7. Epub 2007/06/08. doi:
- 342 10.3201/eid1305.070015. PubMed PMID: 17553261; PubMed Central PMCID: PMCPMC2738459.
- 343 24. Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, Maitland K, et al. Defining childhood severe
- falciparum malaria for intervention studies. PLoS Med. 2007;4(8):e251. Epub 2007/08/24. doi:
- 345 10.1371/journal.pmed.0040251. PubMed PMID: 17713980; PubMed Central PMCID: PMCPMC1949845.

- 346 25. Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, et al. Effect of ten-valent
- 347 pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a
- 348 longitudinal surveillance study. Lancet. 2019;393(10186):2146-54. Epub 2019/04/20. doi: 10.1016/S0140-

349 6736(18)33005-8. PubMed PMID: 31000194; PubMed Central PMCID: PMCPMC6548991.

26. Berkley JA, Mwangi I, Ngetsa CJ, Mwarumba S, Lowe BS, Marsh K, et al. Diagnosis of acute

- bacterial meningitis in children at a district hospital in sub-Saharan Africa. Lancet. 2001;357(9270):1753-7.
- 352 Epub 2001/06/14. doi: 10.1016/S0140-6736(00)04897-2. PubMed PMID: 11403812.
- 27. Maljkovic Berry I, Eyase F, Pollett S, Konongoi SL, Joyce MG, Figueroa K, et al. Global Outbreaks
- and Origins of a Chikungunya Virus Variant Carrying Mutations Which May Increase Fitness for Aedes

aegypti: Revelations from the 2016 Mandera, Kenya Outbreak. Am J Trop Med Hyg. 2019;100(5):1249-57.

- 356 Epub 2019/03/13. doi: 10.4269/ajtmh.18-0980. PubMed PMID: 30860010; PubMed Central PMCID:
- 357 PMCPMC6493958.
- 258 28. Contopoulos-Ioannidis D, Newman-Lindsay S, Chow C, LaBeaud AD. Mother-to-child transmission
- of Chikungunya virus: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2018;12(6):e0006510.
- 360 Epub 2018/06/14. doi: 10.1371/journal.pntd.0006510. PubMed PMID: 29897898; PubMed Central PMCID:
- 361 PMCPMC6075784.
- 362 29. Muthumbi E, Morpeth SC, Ooko M, Mwanzu A, Mwarumba S, Mturi N, et al. Invasive
- 363 Salmonellosis in Kilifi, Kenya. Clin Infect Dis. 2015;61 Suppl 4:S290-301. Epub 2015/10/10. doi:
- 364 10.1093/cid/civ737. PubMed PMID: 26449944; PubMed Central PMCID: PMCPMC4596936.
- 365 30. Pezzi L, Reusken CB, Weaver SC, Drexler JF, Busch M, LaBeaud AD, et al. GloPID-R report on
- 366 Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics. Antiviral Res. 2019;166:66-
- 367 81. Epub 2019/03/25. doi: 10.1016/j.antiviral.2019.03.009. PubMed PMID: 30905821.
- 368 31. Mallewa M, Vallely P, Faragher B, Banda D, Klapper P, Mukaka M, et al. Viral CNS infections in
- children from a malaria-endemic area of Malawi: a prospective cohort study. Lancet Glob Health.
- 370 2013;1(3):e153-60. Epub 2014/04/22. doi: 10.1016/S2214-109X(13)70060-3. PubMed PMID: 24748325;
- 371 PubMed Central PMCID: PMCPMC3986031.
- 372

373 TABLES

Table 1: Demographic and clinical features of patients screened for CHIKV infection

	CHIKV positive	CHIKV negative	P value
	(N=367)	(N=3613)	
Sex – no. (%)			0.39
Female	161 (43.9)	1501 (41.5)	
Age group – no. (%)			0.39
<3 months	148 (40.3)	1641 (45.4)	
3 to <12 months	36 (9.8)	306 (8.5)	
1 to <5 years	124 (33.8)	1164 (32.2)	
5 to <10 years	48 (13.1)	399 (11.0)	
10 to 15 years	11 (3.0)	103 (2.8)	
Year of admission – no. (%)			< 0.001
2014	68 (18.5)	918 (25.4)	
2015	91 (24.8)	895 (24.8)	
2016	144 (39.2)	639 (17.7)	
2017	33 (9.0)	457 (12.6)	
2018	31 (8.4)	704 (19.5)	
Season – no. (%)			0.32
Jan - Mar	92 (25.1)	986 (27.3)	
Apr - Jun	110 (30.0)	995 (27.5)	
Jul - Sep	90 (24.5)	792 (21.9)	
Oct - Dec	75 (20.4)	840 (23.2)	
Admission characteristics			
Duration (days) of hospitalization (median, IQR)	3 (2, 6)	4 (2, 7)	0.26
Needed blood transfusion (no., %)	22 (6.0)	185 (5.1)	0.46
General symptoms – no. (%)			
Fever	279 (76.0)	2683 (74.3)	0.46
Vomiting	57 (15.5)	548 (15.2)	0.85
Cough	60 (16.3)	629 (17.4)	0.61
Diarrhea	20 (5.4)	251 (6.9)	0.28
Jaundice	25 (6.8)	312 (8.6)	0.23
Wasting	15 (4.1)	150 (4.1)	0.95
Joint pain	2 (0.5)	10 (0.3)	0.37
Irritability	16 (4.4)	236 (6.5)	0.10
Rash	1 (0.3)	34 (0.9)	0.19
Deep breathing	29 (7.9)	356 (9.8)	0.23

Shock	2 (0.5)	33 (0.9)	0.47
Lymphadenopathy	3 (0.8)	27 (0.7)	0.88
Neurological symptoms – no. (%) [#]			
History of seizures	56 (15.3)	469 (13.0)	0.22
Seizures during current illness*	179 (48.8)	1632 (45.2)	0.19
Headache	19 (5.2)	144 (4.0)	0.27
Bulging fontanelle	10 (2.7)	70 (1.9)	0.31
Neck stiffness	3 (0.8)	81 (2.2)	0.07
Agitation	27 (7.4)	239 (6.6)	0.59
Prostration	56 (15.3)	574 (15.9)	0.75
Impaired consciousness	165 (45.0)	1718 (47.5)	0.34
Coma	82 (22.3)	791 (21.9)	0.84
Laboratory investigations – no. $(\%)^{\dagger}$			
CSF-to-blood glucose ratio <0.67	63 (29.6)	681 (28.7)	0.80
CSF protein > 0.45g/L	154 (43.7)	1607 (46.5)	0.31
CSF Leukocyte count >5/µL	52 (14.7)	567 (16.2)	0.47
CSF turbidity	9 (2.7)	158 (4.8)	0.09
HIV positive	8 (2.8)	73 (2.6)	0.80
Bacteraemia	16 (4.4)	179 (5.0)	0.62
Malaria slide positive	90 (24.7)	815 (22.7)	0.39
Malaria parasite density (>2500/µL)	57 (15.6)	531 (14.8)	0.67
Impaired renal function (creatinine >80µmol/L)	89 (26.5)	894 (28.4)	0.45
Severe anemia (Hb <5g/dL)	13 (3.6)	108 (3.0)	0.56
Hypoglycemia (blood glucose <2.2mmol/l)	15 (6.8)	243 (9.9)	0.12
Thrombocytopenia (platelets <159 x10 ³ / μ L)	81 (22.4)	767 (21.5)	0.71
Leukopenia (WBC count<3.9 x10 ³ /µL)	5 (1.4)	53 (1.5)	0.87
Lymphopenia (Lymphocyte count<1.7 x10 ³ /µL)	37 (10.2)	293 (8.2)	0.19

375

#Symptoms are not mutually exclusive; some patients had seizures and prostration, neck stiffness and
agitation, and other overlaps in symptoms. *Refers to at least one seizure in the last 24 hours. The frequency
of multiple seizures (>2 in the last 24 hours) was comparable between CHIKV-positive and CHIKV-negative
patients (35.2% vs 30.2%, p=0.18); the bulk of seizures were generalized (84.2% and 79.3% for CHIKV
negative and positive children, respectively). †Sample sizes for each variable do not always add up to the
total N for each group due to missing data. Analysis was only performed in those with data available.
Missing data are summarised in Table S1 in the Supplementary Appendix. Abbreviations: IQR –

- 383 interquartile range; HIV human immunodeficiency virus; Hb haemoglobin; WBC white blood cell
- 384 count.
- 385

386

Variable		Chikungunya (N=207)			Cerebral Malaria (N=68)			Acute Bacterial Meningitis (N=22)		
	Categories	n / PYO	O Incidence/100,000	IRR	n / PYO	Incidence/100,000	IRR	n / PYO	Incidence/100,000	IRR
			(95% CI)	(95% CI)		(95% CI)	(95% CI)		(95% CI)	(95% (
	Female	95/341753	27.8 (22.7-34)	1	33/341899	9.7 (6.9-13.6)	1	7/341753	2 (1-4.3)	1
ex	Male	112/349835	32 (26.6-38.5)	1.2 (0.6-2.4)	35/350019	10 (7.2-13.9)	1 (0.6-1.7)	15/349835	4.3 (2.6-7.1)	2.1 (0.9-
	<3 months	77/10837	710.5 (568.3-888.4)	1	0/10853	-	-	12/10851	110.6 (62.8-194.7)	1
	3 to <12 months	19/33700	56.4 (36-88.4)	0.1 (0-0.1)	2/33755	5.9 (1.5-23.7)	1	2/33750	5.9 (1.5-23.7)	0.1 (0-0
Age	1 to <5 years	77/179432	42.9 (34.3-53.7)	0.1 (0-0.1)	42/179650	23.4 (17.3-31.6)	3.9 (1-16.3)	1/179697	0.6 (0.1-4)	0 (0-0
	5 to <10 years	28/227125	12.3 (8.5-17.9)	0 (0-0)	20/227148	8.8 (5.7-13.6)	1.5 (0.3-6.4)	3/227227	1.3 (0.4-4.1)	0 (0-0
	10 to 15 years	6/240495	2.5 (1.1-5.6)	0 (0-0)	4/240512	1.7 (0.6-4.4)	0.3 (0.1-1.5)	4/240519	1.7 (0.6-4.4)	0 (0-0
	2014	41/138881	29.52 (21.7-40.1)	1	15/138891	10.8 (6.5-17.9)	1	4/138897	2.9 (1.1-7.7)	1
	2015	50/138008	36.2 (27.5-47.8)	1.2 (0.8-1.9)	24/138042	17.4 (11.7-25.9)	1.6 (0.8-3.1)	6/138062	4.3 (2-9.7)	1.5 (0.4-
ear	2016	79/136770	57.8 (46.3-72)	2 (1.3-2.9)	12/136847	8.8 (5-15.4)	0.8 (0.4-1.7)	5/136877	3.7 (1.5-8.8)	1.3 (0.3-
	2017	18/138861	13 (8.2-20.6)	0.4 (0.3-0.8)	7/138965	5 (2.4-10.6)	0.5 (0.2-1.1)	0/138998	-	-
	2018	19/139067	13.7 (8.7-21.4)	0.5 (0.3-0.8)	10/139172	7.2 (3.9-13.4)	0.7 (0.3-1.5)	7/139209	5 (2.4-10.5)	1.7 (0.5
	Jan - Mar	56/172895	32.4 (24.9-42.1)	1	18/172967	10.4 (6.6-16.5)	1	5/172996	2.9 (1.2-6.9)	1
	Apr - Jun	54/173137	31.2 (23.9-40.7)	1 (0.7-1.4)	15/173216	8.7 (5.2-14.4)	0.8 (0.4-1.7)	9/173245	5.2 (2.7-10)	1.8 (0.6-
eason	Jul - Sep	53/172957	30.6 (23.4-40.1)	0.9 (0.6-1.4)	18/173043	10.4 (6.6-16.5)	1 (0.5-1.9)	3/173076	1.7 (0.6-5.4)	0.6 (0.1-
	Oct - Dec	44/172599	25.5 (19-34.3)	0.8 (0.5-1.2)	17/172692	9.8 (6.1-15.8)	0.9 (0.5-1.8)	5/172726	2.9 (1.2-7)	1 (0.3-3

387 Table 2: Incidence of CHIKV-associated neurological disease among children aged <16 years within the KHDSS during the study period (2014-2018)

388 PYO: person-years observed; IRR: incidence rate ratio

389

390





Chikungunya

Cerebral Malaria

Indian Ocean Coastline

Meningitis

All admissions whose CSF was taken

Kilifi County Hospital

0 1.5 3 6 9 12 Kilometres